血友病市場の市場規模、シェア、成長分析：タイプ別、製品別、セラピー別、治療別、地域別 - 産業予測（2025年～2032年）

血友病の市場規模は2023年に135億米ドルと評価され、予測期間（2025年～2032年）のCAGRは6.6%で、2024年の143億9,000万米ドルから2032年には240億米ドルに成長する見通しです。

血友病治療市場は、最近の遺伝子治療の承認や有望な開発候補品のパイプラインによって、力強い成長が見込まれています。血友病に対する意識の高まりは、新生児早期発見のための政府の取り組みと並んで、市場拡大のさらなる触媒となっています。世界血友病連合によると、2021年10月現在、血友病は主に男性が罹患しており、世界有病率は209,614例と報告されていおり、内訳は165,379例がA型、33,076例がB型、11,159例が不明型です。有病率の高さは、利用可能な治療法の普及に拍車をかけており、効果的な治療法とこの分野での技術革新が急務であることを強調しています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別の機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 主要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

血友病市場規模：タイプ別 & CAGR（2025年～2032年）

• 市場概要
• 血友病A
• 血友病B
• 血友病C
• その他

血友病市場規模：製品別 & CAGR（2025年～2032年）

• 市場概要
• 血漿由来凝固因子濃縮物
• 組換え凝固因子濃縮物
• デスモプレシンと抗線溶薬

血友病市場規模：セラピー別 & CAGR（2025年～2032年）

• 市場概要
• オンデマンド
• 予防

血友病市場規模：治療別 & CAGR（2025年～2032年）

• 市場概要
• 補充療法
• ITI療法
• 遺伝子治療

血友病市場規模 & CAGR（2025年～2032年）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022年～2024年）

主要企業プロファイル

• Bayer AG（ドイツ）
• BioMarin Pharmaceutical Inc.（米国）
• CSL Behring（オーストラリア）
• Kedrion（Italy）
• Novo Nordisk（デンマーク）
• Pfizer Inc.（米国）
• Roche（Chugai Pharmaceutical Co.）（スイス/日本）
• Sanofi（Genzyme Corporation）（フランス/米国）
• Takeda Pharmaceutical（Shire Plc.）（日本/アイルランド）
• Grifols（スペイン）
• Octapharma（スイス）
• F. Hoffmann-La Roche Ltd（スイス）
• Biogen（米国）
• Baxalta（米国）
• LFB Group（フランス）
• Bioverativ Inc.（米国）
• Bio Products Laboratory Ltd.（英国）
• Kogenate（ドイツ）
• Sangamo Therapeutics, Inc.（米国）

結論と推奨事項

Hemophilia Market size was valued at USD 13.5 billion in 2023 and is poised to grow from USD 14.39 billion in 2024 to USD 24.0 billion by 2032, growing at a CAGR of 6.6% during the forecast period (2025-2032).

The hemophilia treatment market is poised for robust growth, spurred by recent gene therapy approvals and a pipeline of promising developmental candidates. Heightened awareness of hemophilia, alongside government initiatives for early neonatal detection, is further catalyzing market expansion. According to the World Federation of Hemophilia, as of October 2021, hemophilia predominantly affects males, with a reported global prevalence of 209,614 cases-165,379 of which are type A, 33,076 type B, and 11,159 of unknown type. The substantial prevalence rates are fueling increased adoption of available therapies, underscoring the urgent need for effective treatments and innovation within the sector, thereby positioning hemophilia management as a critical area of focus for healthcare providers and pharmaceutical companies alike.

Top-down and bottom-up approaches were used to estimate and validate the size of the Hemophilia market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Hemophilia Market Segments Analysis

Global Hemophilia Market is segmented by Type, Product, Therapy, Treatment and Region. Based on Type, the market is segmented into Hemophilia A, Hemophilia B, Hemophilia C and Others. Based on Product, the market is segmented into Plasma derived coagulation factor concentrates, Recombinant coagulation factor concentrates and Desmopressin and antifibrinolytic agents. Based on Therapy, the market is segmented into On-demand and Prophylaxis. Based on Treatment, the market is segmented into Replacement therapy, ITI therapy and Gene Therapy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Hemophilia Market

The hemophilia market is being driven by significant advancements in medical technology, particularly in gene therapy, recombinant factor concentrates, and personalized medicine. These innovations have revolutionized treatment strategies, offering patients improved therapeutic options that lead to better health outcomes and enhanced quality of life. As these cutting-edge therapies continue to evolve, they are not only transforming the management of hemophilia but also fostering a more tailored approach to treatment that resonates with individual patient needs. Consequently, the growing adoption of these advanced therapies is a key factor propelling the hemophilia market forward.

Restraints in the Hemophilia Market

The hemophilia market faces significant restraints primarily due to the high costs associated with treatment options, especially with the advent of novel therapies like gene therapy. These advancements, while promising, often come with hefty price tags that can create financial burdens for patients and healthcare systems alike. This economic barrier restricts access to cutting-edge treatments, which may hinder patient outcomes and overall disease management. Consequently, the financial implications of these innovative therapies remain a critical challenge within the hemophilia market, impacting the availability and accessibility of essential care for those affected by this bleeding disorder.

Market Trends of the Hemophilia Market

The hemophilia market is experiencing a significant shift towards gene therapy as a transformative treatment modality. This trend is driven by the increasing recognition of gene therapy's potential to address the root genetic causes of hemophilia, offering patients durable solutions that could replace the need for traditional factor replacement therapies. Advances in viral vector technologies and a deeper understanding of genetic engineering have catalyzed this shift, leading to numerous successful clinical trials that validate the efficacy and safety of gene therapies. As these innovations continue to unfold, they promise to enhance patient quality of life, reduce treatment frequency, and reshape the overall landscape of hemophilia care.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Hemophilia Market Size by Type & CAGR (2025-2032)

• Market Overview
• Hemophilia A
• Hemophilia B
• Hemophilia C
• Others

Global Hemophilia Market Size by Product & CAGR (2025-2032)

• Market Overview
• Plasma derived coagulation factor concentrates
• Recombinant coagulation factor concentrates
• Desmopressin and antifibrinolytic agents

Global Hemophilia Market Size by Therapy & CAGR (2025-2032)

• Market Overview
• On-demand
• Prophylaxis

Global Hemophilia Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Replacement therapy
• ITI therapy
• Gene Therapy

Global Hemophilia Market Size & CAGR (2025-2032)

• North America (Type, Product, Therapy, Treatment)
  • US
  • Canada
• Europe (Type, Product, Therapy, Treatment)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Product, Therapy, Treatment)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Product, Therapy, Treatment)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Product, Therapy, Treatment)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioMarin Pharmaceutical Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Behring (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kedrion (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Chugai Pharmaceutical Co.) (Switzerland/Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (Genzyme Corporation) (France/United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical (Shire Plc.) (Japan/Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Octapharma (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxalta (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LFB Group (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bioverativ Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio Products Laboratory Ltd. (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kogenate (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sangamo Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations